HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 07, July 2021 – Ageing Better – Breakthroughs and Innovations for a Greying World       » A Plant-Based Remedy for Big, Broken Hearts       » Fuelling the Future with Multi-Element Alloys and Green Hydrogen       » RADICA: A Radical, Rapid Method for Accurate Detection of Viruses       » Untangling the Twists of Alzheimer’s Plaques       » Turning Aquaculture Trash to Treasure for Tissue Repair      
Vol 25, No. 06, June 2021   |   Issue PDF view/purchase
EYE ON CHINA
New Antibody Designed for Better Tumour Inhibition
Researchers from High Magnetic Field Laboratory of the Hefei Institutes of Physical Science (HFIPS), in a collaboration with a lab from the Institute of Biophysics, reported the structural basis of a new antibody and its ability to inhibit CD146-mediated endothelial cells (EC).

CD146 is an adhesion molecule that plays important roles in angiogenesis, cancer metastasis, and immune response. Professor Yan Xiyun's lab has been focused on the function of CD146 and the mechanism underlain, aiming to develop antibody drugs targeting CD146. Their previous studies demonstrated that CD146 triggered the signalling cascade via dimerization induced by various ligands. AA98, a monoclonal antibody (mAb) binding to CD146, shows inhibitory effects on tumour growth. However, the structural basis of CD146 activation and AA98 inhibition remains to be addressed.

Recently, Professor Xie Can from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science (HFIPS), in a collaboration with Professor Yan Xiyun's lab from the Institute of Biophysics, reported the structural basis of mAb AA98's inhibition on CD146-mediated endothelial cells (EC) activation and designed higher affinity monoclonal antibody HA98 for cancer treatment.

In this research, the researchers described a crystal structure of the CD146/AA98 Fab complex at a resolution of 2.8 angstrom. Structural analysis elucidated AA98 stabilized CD146 in monomer conformation thus inhibited EC activation. A higher-affinity AA98 variant (named HA98) was then rationally designed based on the complex structure in this study.

Further experiments on animal model with HA98 revealed superior inhibitory effects on tumour growth to those of AA98, which suggested future applications of this antibody in cancer therapy.

“There was so much to do,” said Xie, “this collaborative project was initiated about 9 years ago. The crystal structure of CD146/AA98 complex was only the first step, and how to use the structural information we obtained in rational design was much more attractive to us. Researchers from two labs have been working together from different perspectives to bring up a better antibody for potential cancer therapy. The collaboration was successful indeed.”

NEWS CRUNCH  
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare
news Anti-Pandemic Forum to be Hosted by Top-Notch American and Chinese Scientists
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy